We know that the supplement world can be confusing, with many brands making big claims without the science to back them up
BAC WATER 30ml $29.95 test test Research Use Only (RUO)
To qualify, you need to meet one of the following requirements when starting GLP-1 treatment: A BMI (body mass index) of 35 or higher A BMI between 30 and 34.99, with one or more additional conditions: Diastolic heart failure Uncontrolled high blood pressure/hypertension Chronic kidney disease, stage 3a or higher Prediabetes Previous heart attack or stroke Blocked arteries in arms or legs with symptoms A BMI between 27 and 29.99, with one or more additional conditions: Prediabetes Previous heart attack or stroke Blocked arteries in arms or legs with symptoms Medicare beneficiaries who have sleep apnea, diabetes or fatty liver disease can't access the program, but their Medicare Part D insurance might cover their GLP-1s separately based on those diagnoses

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial examining canagliflozin in CKD with proteinuria has been stopped at a planned interim analysis for achieving the primary efficacy endpoint [62]
(27878767, 34517272) If you dont have access to free valproate levels, then laboratory monitoring may be more accurate with phenobarbital